Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

13.24
-1.2100-8.37%
Pre-market: 13.240.00000.00%04:16 EDT
Volume:3.65M
Turnover:49.34M
Market Cap:1.25B
PE:-4.20
High:14.47
Open:14.47
Low:13.21
Close:14.45
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:2.67
T/O Rate:4.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.81
PE(LYR):-3.91

Loading ...

Replimune Jumps After $150 Mln Equity Offering for Skin Cancer Drug

Reuters
·
Aug 11

Replimune Group, - Prices Offering of 9.7 Mln Shares at $12.06 Per Share

THOMSON REUTERS
·
Aug 10

Replimune Group, - Offers 2.7 Mln Pre-Funded Warrants at $12.06 Per Warrant

THOMSON REUTERS
·
Aug 10

Replimune Prices USD 150 Million Follow-on Stock Offering at USD 12.06 Per Share

Reuters
·
Aug 10

Replimune Group Price Target Raised to $20.00/Share from $17.00 by JP Morgan

Dow Jones
·
Aug 08

U.S. Stocks on the MOVE-Atlassian, Macerich, DoubleVerify

Reuters
·
Aug 08

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.

Dow Jones
·
Aug 08

Replimune Slides as FDA Approval Label Tempers Enthusiasm

Reuters
·
Aug 07

Replimune Group, Inc. : Wedbush Raises to Outperform from Neutral; Raises Target Price to $19 from $12

THOMSON REUTERS
·
Aug 07

Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts PT to $19 From $12

MT Newswires Live
·
Aug 07

Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma

TIPRANKS
·
Aug 07

Zentalis Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Replimune Group Melanoma Therapy Tudriqev Priced at $450,000 Per Typical Real-World Patient

THOMSON REUTERS
·
Aug 07

US FDA Approves Replimune's Skin Cancer Drug

Reuters
·
Aug 07

Replimune Group - Approval Based on Objective Response Rate and Duration of Response; Confirmatory Trial Required

THOMSON REUTERS
·
Aug 07

Replimune Announces FDA Accelerated Approval of Tudriqevtm in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an Anti-Pd-1 Based Regimen

THOMSON REUTERS
·
Aug 07

Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11

MT Newswires Live
·
Aug 04

Replimune Group Raised to Outperform from Market Perform by Leerink Partners

Dow Jones
·
Aug 04

Replimune Group Inc : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $17.00 from $11.00

THOMSON REUTERS
·
Aug 04

Top Midday Gainers

MT Newswires Live
·
Aug 01